GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Atai Life Sciences N.V.
Atai Life Sciences is a biotech company investing in the development of psychedelic drugs for the treatment of mental disorders. Its stock price represents a venture bet on the future of this controversial but potentially revolutionary field of medicine.
Share prices of companies in the market segment - Pharma psycho
Atai is a biotech platform investing in and developing psychedelic drugs for the treatment of mental disorders. We classify it as part of the Pharma Psycho sector, and the chart below reflects the dynamics of this entire innovative, yet high-risk, pharmaceutical segment.
Broad Market Index - GURU.Markets
Atai Life Sciences is a biotech company developing psychedelic-based drugs for the treatment of mental disorders. As a component of the GURU.Markets index, it represents the emerging and promising psychopharmacology sector. The chart below represents the entire market. See how Atai shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ATAI - Daily change in the company's share price Atai Life Sciences N.V.
Change_co for Atai Life Sciences, a biotech company focused on psychedelics, reflects extreme volatility. Daily fluctuations indicate sensitivity to news about clinical trials and regulatory changes. This metric is important for analyzing speculative biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Atai Life Sciences N.V. is a biotech company working with psychedelics. This chart highlights the sector's extreme volatility. Comparison with ATAI's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
Atai Life Sciences is a biopharmaceutical company operating in the psychedelic medicine sector. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Atai Life Sciences N.V.
Atai is one of the leading companies developing psychedelic-based drugs. Its year-over-year performance reflects both progress in clinical trials and the evolving regulatory attitudes toward this new class of drugs.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Atai Life Sciences N.V. is a biotechnology company developing psychedelic drugs for the treatment of mental disorders. Its stock price is entirely speculative and based on investor belief in the future legalization and medical potential of these substances, not on current financial performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atai, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its price chart reflects the hopes, risks, and regulatory changes surrounding one of the most controversial, yet potentially breakthrough, areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Atai Life Sciences N.V.
Atai's chart reflects the development of the pioneering and highly speculative field of psychedelic medicine. Its monthly valuation is determined not by sales, but by clinical trial milestones across its diverse portfolio of drugs targeting mental disorders. FDA comments and evolving public perception of psychedelics are also key factors.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Biotechnology using psychedelics to treat mental disorders is one of the most speculative areas of medicine. The chart below reflects the hype and volatility associated with expectations of clinical breakthroughs and regulatory changes. At the forefront of this movement is a company like Atai Life Sciences.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Atai Life Sciences, which invests in the development of psychedelics for the treatment of mental disorders, is a venture capital bet. The company's shares move not in sync with the market, but on news about clinical trials and legislative changes in this controversial field.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Atai Life Sciences N.V.
Short-term fluctuations in Atai Life Sciences, which invests in the development of psychedelics for the treatment of mental disorders, are extremely high. News about legislative changes, clinical trial results of its portfolio companies, or DEA/FDA decisions cause sharp price movements.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Atai Life Sciences shares, like those of the entire nascent psychedelic medicine sector, are moving on the back of a broader news cycle and expectations. Regulatory shifts and key research results are creating extreme volatility for everyone. The chart will reveal whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Atai Life Sciences, as a speculative biotech, is an asset with an exorbitantly high beta. Its shares soar on general market optimism and plummet at the slightest fear. The chart clearly demonstrates this exaggerated tracking of market sentiment.
Market capitalization of the company, segment and market as a whole
ATAI - Market capitalization of the company Atai Life Sciences N.V.
Atai Life Sciences' market capitalization chart is a visualization of the hopes for a revolution in the treatment of mental disorders using psychedelics. It reflects investors' assessment of the company's broad development portfolio. Its speculative dynamics tell the story of how the market weighs a huge potential market against high regulatory and scientific barriers.
ATAI - Share of the company's market capitalization Atai Life Sciences N.V. within the market segment - Pharma psycho
atai Life Sciences is a biotech company developing psychedelic and other drugs for the treatment of mental disorders. Its market share reflects its leadership in this revolutionary approach. The chart shows how the market perceives the potential of its platform to revolutionize the treatment of depression and addiction.
Market capitalization of the market segment - Pharma psycho
Atai Life Sciences is a biotech platform investing in the development of psychedelics for the treatment of mental disorders. The chart below shows the market capitalization of psychopharmacology. Its dynamics reflect hopes for a revolution in psychiatry, and Atai is at the forefront of this bold scientific movement.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible on the chart are exploring new approaches to treating mental disorders. Atai Life Sciences is investing in and developing psychedelic compounds for the treatment of depression and other conditions. Its market cap represents a very risky bet on a paradigm shift in psychiatry.
Book value capitalization of the company, segment and market as a whole
ATAI - Book value capitalization of the company Atai Life Sciences N.V.
Atai Life Sciences is a capital investment in psychedelic medicine research. The company's book value, which is in the R&D stage, is comprised of investors' cash. It is using these financial assets to conduct clinical trials of compounds for the treatment of mental disorders.
ATAI - Share of the company's book capitalization Atai Life Sciences N.V. within the market segment - Pharma psycho
Atai Life Sciences, a psychedelic drug development platform, has a light asset structure. Its sector share is derived from investments in R&D and laboratories. The chart shows that at this stage, its value is derived from intellectual property and clinical research.
Market segment balance sheet capitalization - Pharma psycho
Atai Life Sciences is a biotech platform. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Atai uses a decentralized model: it invests in several asset-light R&D companies rather than building a single, large entity.
Book value of all companies included in the broad market index - GURU.Markets
Atai Life Sciences is a biotech company developing psychedelic and other drugs for the treatment of mental disorders. Its book value is derived from the capital it invests in dozens of clinical programs through its decentralized platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Atai Life Sciences N.V.
Atai Life Sciences is a biotech platform. Its book value is its cash and investments. Its market capitalization is the premium investors are betting on one of its many psychedelic projects becoming a successful drug.
Market to book capitalization ratio in a market segment - Pharma psycho
Atai Life Sciences invests in and develops psychedelic drugs for the treatment of mental disorders. It is a venture-backed biotech company. The chart shows that its value is based almost entirely on expectations for future clinical trials, rather than on current tangible assets.
Market to book capitalization ratio for the market as a whole
Atai Life Sciences is a biotech company working in the field of psychedelic medicine for the treatment of mental disorders. Given the average market valuations shown in this chart, its valuation is highly speculative and based on hopes that its drug candidates will pass clinical trials and transform approaches to treating depression and PTSD.
Debts of the company, segment and market as a whole
ATAI - Company debts Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. This is a cutting-edge but risky field, requiring massive investments in clinical research with no guarantee of success. This chart shows how the company is funding its numerous research programs toward potential commercialization.
Market segment debts - Pharma psycho
Atai Life Sciences is a biotech company working in the field of psychedelic medicine. This industry is in its earliest stages of development, and companies in it are entirely focused on clinical research. They typically have no revenue or debt. This chart depicts the company's financial structure, which relies on equity to fund R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Atai Life Sciences N.V.
Atai Life Sciences is investing in the development of psychedelic drugs for the treatment of mental disorders. This chart shows the company's financial structure at the research stage. For a biotech company without revenue, debt is a major risk. Its presence indicates creditor confidence, but also vulnerability, as the future depends on the success of clinical trials and regulatory approval.
Market segment debt to market segment book capitalization - Pharma psycho
Atai Life Sciences is a biotech company researching psychedelics for the treatment of mental disorders. This is a cutting-edge but risky field, requiring massive investments in clinical research. The chart shows the overall debt burden in the pharmaceutical industry, helping to understand how Atai and other pioneers in this field finance their expensive research.
Debt to book value of all companies in the market
Atai Life Sciences N.V. is a biotech company working in the field of mental health using psychedelics. It is in the research stage and requires funding. This chart provides insight into the overall cost of capital, which helps understand why Atai may prefer equity financing over debt at this early, risky stage.
P/E of the company, segment and market as a whole
P/E - Atai Life Sciences N.V.
For Atai Life Sciences, a company developing psychedelics for the treatment of mental disorders, the P/E ratio is irrelevant. The company has no profit, and its valuation on this chart is arbitrary. The real value is a speculative bet that its drugs will pass clinical trials and revolutionize psychiatry.
P/E of the market segment - Pharma psycho
Atai Life Sciences is a biotech company focused on mental health. It invests in and develops psychedelic and non-psychedelic compounds for the treatment of depression, addiction, and anxiety disorders. This chart shows the average valuation for the biotech sector, reflecting investor sentiment toward this innovative yet risky field.
P/E of the market as a whole
Atai Life Sciences is a biotech company working in the field of psychedelic medicine for the treatment of mental disorders. Its valuation is a pure bet on the legalization and medical use of these substances. It has no connection to the general economic cycles reflected in this chart. Its fate is decided in laboratories, the minds of regulators, and the public consciousness.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and anxiety. Its valuation is based on the future potential of this new class of drugs. This chart reflects investors' confidence in the success of clinical trials and the potential for paradigm shift in psychiatry.
%20P%2FE%20Atai%20Life%20Sciences%20N.V.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Atai-Life-Sciences-N.V.&v=1772675915057 "Chart of the company's future (projected) P/E Atai Life Sciences N.V.")
Future (projected) P/E of the market segment - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelic compounds for the treatment of mental disorders. This chart reflects general profitability expectations for the pharmaceutical sector. ATAI's position relative to the average reflects investors' belief in the revolutionary potential of this new class of therapy and their willingness to finance the risks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772675915093 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Atai Life Sciences is a biotech company investing in the development of psychedelics for the treatment of mental disorders. This is a highly risky and innovative field. This chart shows the market's risk tolerance. During bull markets and periods of optimism, investors are much more willing to invest in such breakthrough, yet speculative, ideas.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772675915182 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders such as depression and anxiety. Currently in clinical trials, its schedule primarily reflects R&D costs. Potential profit depends on the future approval of its drugs.
Profit of companies in the market segment - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelic compounds for the treatment of mental disorders. This is a cutting-edge but risky field. This chart reflects the total revenue in its pharmaceutical segment. It demonstrates the overall investment appeal and progress in commercializing innovative approaches to treating mental illnesses.
Overall market profit
Atai Life Sciences is investing in the development of psychedelic drugs for the treatment of mental disorders. This is a cutting-edge and risky field, heavily dependent on venture capital. The overall economic upturn, reflected in the chart, is increasing investors' risk appetite and allowing Atai to raise funds for expensive clinical trials, advancing science.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Atai Life Sciences N.V.
Atai Life Sciences is a biotech platform investing in the development of psychedelics for the treatment of mental disorders. Future profits are entirely dependent on the success of clinical trials and changes in the regulatory environment. This chart summarizes analysts' speculative forecasts regarding the potential of this new class of therapy.
%20profit%20of%20the%20company%20Atai%20Life%20Sciences%20N.V.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Atai-Life-Sciences-N.V.&v=1772675915317 "Graph of future (projected) profit of the company Atai Life Sciences N.V.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Atai Life Sciences is a biotech platform investing in the development of psychedelic compounds for the treatment of mental disorders such as depression and anxiety. The company's future depends on regulatory approval and the success of clinical trials. This chart reflects forecasts for the pharmaceutical sector, helping to assess the risks and enormous potential of this innovative medical field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772675915331 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Atai Life Sciences is a biotech company working in the field of mental health using psychedelics. Its value is determined by progress in clinical trials and regulatory decisions, not by current economic conditions. This earnings curve has little bearing on the company's prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772675915361 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Atai Life Sciences N.V.
Atai Life Sciences is a biotech platform investing in the development of psychedelic compounds for the treatment of mental disorders. With near-zero revenue, this chart reflects pure expectations. Its significance reflects investors' bet that the company will be able to legalize and commercialize these innovative therapies.
P/S market segment - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. Future revenue depends on the approval and commercialization of its developments. This chart for the pharmaceutical sector allows you to compare the enormous investor expectations for Atai's innovative approach with those of other companies changing the paradigm in medicine.
P/S of the market as a whole
Atai Life Sciences is a biotech company developing psychedelic drugs to treat mental disorders such as depression and anxiety. Its revenue is currently minimal. This market valuation chart is important for understanding how investors view the enormous, yet risky, potential of this revolutionary approach to treating mental illness.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic compounds for the treatment of mental disorders such as depression and anxiety. This chart shows how investors assess the future commercial potential of its developments. It reflects their belief that the company's drugs will successfully pass trials and receive regulatory approval.
%20P%2FS%20Atai%20Life%20Sciences%20N.V.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Atai-Life-Sciences-N.V.&v=1772675915641 "The graph of the company's future (projected) P/S Atai Life Sciences N.V.")
Future (projected) P/S of the market segment - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelic and other drugs for the treatment of mental disorders such as depression and anxiety. The company's development-stage valuation is based on investors' belief in the therapeutic potential of these new approaches and its ability to successfully conduct clinical trials and obtain approval.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772675915673 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Atai Life Sciences is a biotech company developing psychedelic therapies for the treatment of mental disorders. It is a business at the cutting edge of science. The revenue growth projections presented here do not take into account the potential of such revolutionary approaches to medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772675915698 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic compounds for the treatment of mental disorders. Being in clinical development, its revenue, if shown, likely comes from payments from pharmaceutical partners for joint projects, rather than from sales of its own drugs.
Sales of companies in the market segment - Pharma psycho
Atai Life Sciences (ATAI) is a biotech platform investing in the development of psychedelics and other innovative drugs for the treatment of mental disorders such as depression and anxiety. This chart shows revenue from the pharmaceutical sector, where Atai is at the forefront of the psychiatric revolution, exploring new approaches to therapy.
Overall market sales
Atai Life Sciences is a biotech company researching psychedelics for the treatment of mental disorders. While its success depends on clinical trial results, the overall economic situation, reflected in the chart, impacts access to capital. Economic growth and market optimism allow innovative but risky companies like Atai to raise funding.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic and other drugs for the treatment of mental disorders. Its future revenue is entirely dependent on the success of clinical trials and regulatory approval. This chart reflects analyst forecasts, which essentially assess the likelihood of commercial success for their innovative approaches in psychiatry.
%20sales%20of%20the%20company%20Atai%20Life%20Sciences%20N.V.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Atai-Life-Sciences-N.V.&v=1772675915778 "Schedule of future (projected) sales of the company Atai Life Sciences N.V.")
Future (projected) sales of companies in the market segment - Pharma psycho
Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing psychedelics and other drugs for the treatment of mental disorders. This forecast chart reflects the potential future revenue from their development pipeline. It represents analysts' perspective on the commercialization of this innovative class of drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772675915788 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Atai Life Sciences is a biotech company focused on mental health, developing psychedelic and other innovative drugs. Its valuation is based on its research potential. This graph, reflecting investors' risk appetite, impacts the availability of capital for funding breakthrough but high-risk medical advances.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772675915817 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Atai Life Sciences N.V.
Atai Life Sciences is a biotech company investing in and developing psychedelic drugs for the treatment of mental disorders. Its financial performance currently reflects significant expenditures on research and clinical trials. The chart below shows current profitability, which is a guarantee of future success should the drugs be approved by regulators.
Market segment marginality - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelic and other drugs for the treatment of mental disorders such as depression and anxiety. This chart reflects its operating expenses during the research stage. As with other biotech companies without revenue, this indicator's dynamics are important for assessing cost control.
Market marginality as a whole
Atai Life Sciences is a biotech company researching psychedelics for the treatment of mental disorders. Its market capitalization depends on investors' appetite for innovative but risky ventures. This total return chart reflects this appetite. During periods of economic growth and high margins, investors are more inclined to fund breakthrough scientific research.
Employees in the company, segment and market as a whole
Number of employees in the company Atai Life Sciences N.V.
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. Its staff consists primarily of scientists. The team's growth, visible in the graph, directly reflects the number and progress of its clinical programs, a key indicator of the development of its innovation portfolio.
Share of the company's employees Atai Life Sciences N.V. within the market segment - Pharma psycho
Atai Life Sciences is a biotech platform investing in the development of psychedelic drugs for the treatment of mental disorders. Its structure is unique: it supports a portfolio of several development companies. This chart reflects the cumulative human capital invested in this cutting-edge and complex field of medicine across the entire Atai ecosystem.
Number of employees in the market segment - Pharma psycho
Atai Life Sciences is a biotech platform developing psychedelics for the treatment of mental disorders. The employment dynamics in the psychopharmacology sector, seen here, reflect the legalization and growing interest in this field. For Atai, this means the formation of a new pool of specialists and scientists, but also increased competition for leadership in the nascent industry.
Number of employees in the market as a whole
Atai Life Sciences is a biopharmaceutical company developing psychedelic drugs for the treatment of mental disorders. Its hiring is driven by progress in research and clinical trials. It is at the forefront of this emerging medical field and seeks talent from the broader labor market represented here.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Atai Life Sciences N.V. (ATAI)
Atai Life Sciences is a biotech platform investing in and developing psychedelic and other drugs for the treatment of mental disorders. The company's entire capital is a portfolio of intellectual property. This metric demonstrates how the market evaluates the potential of an entire field of medicine, where enormous value is created by a small team of scientists and managers.
%20of%20the%20company%20Atai%20Life%20Sciences%20N.V.%20(ATAI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Atai-Life-Sciences-N.V.-ATAI&v=1772675916136 "Chart of market capitalization per employee (in thousands of dollars) of the company Atai Life Sciences N.V. (ATAI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Atai Life Sciences is a biotech company developing psychedelics for the treatment of mental disorders. Its valuation is a bet on a future revolution in psychiatry. Its high market capitalization per employee reflects the enormous potential of its research, with each scientist working to create a multi-billion dollar market.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772675916145 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Atai Life Sciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. The chart reflects a high valuation of its scientific potential. The company's entire value is based on the hope for future treatments. This indicator demonstrates the enormous value the market places on the research of each scientist on the team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772675916150 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Atai Life Sciences N.V. (ATAI)
Atai Life Sciences is a biotech company investing in and developing psychedelics for the treatment of mental disorders. It is a venture-backed R&D platform. Profit is currently negative. This chart does not show revenue, but rather the investment (expenses) per employee, which are allocated to clinical research and the development of new drugs.
%20Chart%20Atai%20Life%20Sciences%20N.V.%20(ATAI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Atai-Life-Sciences-N.V.-ATAI&v=1772675916175 "Company Profit Per Employee (in thousands of dollars) Chart Atai Life Sciences N.V. (ATAI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Atai Life Sciences is a biotech platform investing in and developing psychedelics for the treatment of mental disorders. It is an early-stage venture capital firm. This metric (loss per employee) reflects the intensity of R&D and clinical trials. Investors view this as the cost of "growing" a portfolio of potential blockbusters.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772675916199 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Atai Life Sciences is a biotech company working in the field of mental health, specifically researching psychedelics for the treatment of depression and anxiety. It is a venture-backed company at the R&D stage. The company invests in its research portfolio. There is no profit. This chart is important to understand that in this sector, employees (scientists) are a cost center, creating intellectual property that (potentially) will generate revenue in the future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772675916253 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Atai Life Sciences N.V. (ATAI)
Atai Life Sciences is a biotech company developing psychedelic compounds for the treatment of mental disorders. Being in clinical trials, it has no commercial revenue. This graph would show zero, emphasizing that its value lies in the potential of its R&D portfolio.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Atai-Life-Sciences-N.V.-ATAI&v=1772675916280 "Sales chart per company employee Atai Life Sciences N.V. (ATAI)")
Sales per employee in the market segment - Pharma psycho
Atai Life Sciences (ATAI) is a biotech company developing treatments for mental disorders, including psychedelic compounds. This chart shows the average revenue per employee in the sector. For a company in the R&D stage, it is important for assessing the efficiency of capital and personnel utilization.
Sales per employee for the market as a whole
Atai Life Sciences (ATAI) is a biotech company working at the forefront of research, developing psychedelics and similar compounds for the treatment of mental disorders. Like many companies in this sector, ATAI has no commercial products yet. This figure is likely close to zero, as the company is in an intensive R&D phase, with a large staff of scientists working to generate future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Atai Life Sciences N.V. (ATAI)
Atai Life Sciences (ATAI) is a biotech platform investing in and developing psychedelics (such as psilocybin) for the treatment of mental disorders. This is a highly speculative and regulatoryly complex field. This chart shows the volume of short positions. The high level of these bets reflects the enormous risks: investors are betting that these compounds will not receive FDA approval or public acceptance. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Atai-Life-Sciences-N.V.-ATAI&v=1772675916362 "Short Shares Chart for the Company Atai Life Sciences N.V. (ATAI)")
Shares shorted by market segment - Pharma psycho
Atai is a biotech platform investing in and developing psychedelic-based drugs (psilocybin, ketamine) for the treatment of mental disorders. This chart shows the overall sentiment in the sector. It reflects extreme investor skepticism about the sector due to regulatory and R&D risks.
Shares shorted by the overall market
Atai Life Sciences is a venture platform investing in the development of psychedelics for the treatment of mental disorders. This is one of the most speculative areas of biotech. When this market fear indicator rises, investors flee risk. Unprofitable "dream" stocks like ATAI are the first to sell off in anticipation of a "nuclear winter" in venture capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Atai Life Sciences N.V. (ATAI)
Atai Life Sciences (ATAI) is a biotech company operating in the psychedelics sector. They invest in and develop drugs based on psilocybin and other compounds for the treatment of mental disorders. This is a highly speculative field. This chart measures hype. It shows "overheated" (above 70) on news of decriminalization or "oversold" (below 30) amid trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Atai-Life-Sciences-N.V.-ATAI&v=1772675916425 "RSI 14 indicator chart for the company's stock Atai Life Sciences N.V. (ATAI)")
RSI 14 Market Segment - Pharma psycho
Atai Life Sciences (ATAI) is a biotech platform investing in and developing psychedelics (and related compounds) for the treatment of mental disorders (depression, PTSD). This chart tracks the collective hype in the Pharma/Psychedelics sector. It shows when the entire industry is overheated by speculative hype or oversold by a series of setbacks.
RSI 14 for the overall market
Atai Life Sciences (ATAI), a psychedelic development company. This chart is its lifeline. Its business is pure R&D "on the edge." During periods of euphoria, investors are willing to "buy the dream" and fund the most speculative projects. In moments of panic, capital flees such "scientific projects" first.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATAI (Atai Life Sciences N.V.)
Atai Life Sciences is a biotech company working at the intersection of psychiatry and psychedelics. It is developing a new generation of drugs based on these compounds for the treatment of depression and anxiety. This chart reflects the analyst consensus on the high risk and potential of this new class of therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATAI-Atai-Life-Sciences-N.V.&v=1772675916496 "A chart showing analyst consensus forecasts for the expected stock price. ATAI (Atai Life Sciences N.V.)")
The difference between the consensus estimate and the actual stock price ATAI (Atai Life Sciences N.V.)
Atai Life Sciences is a biotech platform investing in the development of psychedelics (such as psilocybin and ketamine) as treatments for mental disorders (such as depression and PTSD). This chart reflects analysts' highly speculative expectations regarding the legalization and medical use of these substances.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATAI-Atai-Life-Sciences-N.V.&v=1772675916518 "A chart showing the difference between the consensus forecast and the actual stock price. ATAI (Atai Life Sciences N.V.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Atai Life Sciences is a biotech company and incubator for the development of psychedelics (psilocybin, ketamine) and other innovative treatments for mental disorders (depression, PTSD). This chart shows general expectations for the pharmaceutical (psycho) sector. It reflects whether experts believe in the legalization and commercialization of these substances.
Analysts' consensus forecast for the overall market share price
Atai Life Sciences is a biotech company operating in the psychedelic medicine sector. They invest in and develop psychedelic-based drugs for the treatment of mental disorders. This chart shows the overall risk appetite. For Atai, operating in a speculative and not yet fully legalized sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Atai Life Sciences N.V.
Atai Life Sciences is not just a biotech company, but a platform (holding) at the forefront of psychedelic medicine. They invest in and develop a portfolio of drugs (including psilocybin and ketamine derivatives) for the treatment of severe mental disorders. This chart is an assessment of the entire sector. It reflects the market's confidence in the therapeutic potential of these substances and the complex regulatory barriers they face.
AKIMA Market Segment Index - Pharma psycho
Atai Life Sciences (ATAI) is a leader in the psychedelic revolution; it's a biotech holding company that invests in and develops (through its subsidiaries) a portfolio of psychedelic-based drugs (psilocybin, ketamine) for the treatment of depression. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does ATAI's futuristic (and risky) model differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Atai Life Sciences is a biotech company developing drugs to treat mental disorders, including psychedelics. It's at the forefront of psychiatry. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding bold scientific bets like Atai's.
